10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Thursday, January 5, 2012

Wockhardt Ltd:-Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger

Scripscan:Wockhardt Ltd

Story:Wockhardt Limited, a pharmaceutical and biotechnology company, engages in the manufacture and marketing of pharmaceutical products worldwide. It offers steriles, including vials, ampoules, cartridges, lyophilized products, cephalosporins, and pre-filled syringes; biotech products comprising yeast, e-coli, and mammalian cell formulations; oral products, such as tablets, capsules, liquids sachets, pellets, and suspensions; topical products, including creams, ointments, powders, and gels; and active pharmaceutical ingredients, including sterile cephalosporins, chemical synthesis, and peptide synthesis, as well as spray-dried nutrition, denture cleansing tablets, and fixative cream. The company’s biopharmaceutical products include Biovac-B, a hepatitis B vaccine; Wepox, a recombinant erythropoietin for the treatment of anemia; Wosulin, a recombinant human insulin; Wosulin Pen & Cartridge, an automatic insulin delivery device; and Glargine, a novel long-acting insulin, as well as growth stimulating factors. Its products under development comprise WCK 771, an antibiotic that is in Phase II human clinical trials for treating staphylococcal infections like MRSA and VISA; and WCK 1152, which is in Phase I clinical trials to treat respiratory tract infections, including hospital-acquired infections.After having been in the news for all the wrong reasons, Wockhardt has managed to turn the flow in its favour to a great extent last year. While it still carries a huge debt on its books, it has managed to improve its balance sheet in the last six months that seems to have enthused the stock markets. Its debt-to-equity ratio was 2.6 times at the end of the September quarter against 3.4 times seen in March. What has also earned it brownie points is its improved business and cash flows. For the quarter ended September, the pharmaceutical company reported 18 per cent increase in sales to Rs 1,111 crore, helped by growth in its key markets of US, Europe and India.This helped it turnaround its loss of Rs 97 crore in the second quarter of last year to a consolidated net profit of Rs 128 crore this quarter.While volatile exchange rates could dent profitability in the coming quarters, expectations of a debt reduction using the proceeds from the sale of its nutrition business and brands to French Dairy giant Danone SA has buttressed the stock. But for the Rs 320 crore odd that could go to Carol Info Services, a large portion of the sale price of Rs 1,600 crore would accrue to Wockhardt.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner